[MIBI and parathyroid gland function in secondary hyperparathyroidism].

Area of Science:

• Nuclear Medicine
• Nephrology
• Endocrinology

Background:

• Hyperparathyroidism is a common complication in patients with chronic kidney disease.
• Diagnosis and management of uremic hyperparathyroidism are challenging.
• Parathyroid scintigraphy with MIBI is established for primary hyperparathyroidism.

Purpose of the Study:

• To evaluate the utility of double phase parathyroid scintigraphy with MIBI in diagnosing and guiding therapy for uremic hyperparathyroidism.
• To assess the impact of a stimulation test on scintigraphic findings and parathyroid hormone levels.

Main Methods:

• 18 dialysis patients with hyperparathyroidism underwent two MIBI scintigraphy studies.
• A basal study was performed, followed by a stimulation study after vitamin D withdrawal and phosphorus binder cessation.
• Parathyroid hormone (PTHi), calcium, and phosphorus levels were monitored.

Main Results:

• Basal scintigraphy showed positive uptake in 14 patients, correlating with higher PTHi levels.
• The stimulation test significantly increased PTHi and phosphorus levels, with a slight decrease in calcium.
• Scintigraphic uptake scores increased significantly after stimulation, correlating with PTHi levels.

Conclusions:

• MIBI scintigraphy is a valuable tool for assessing parathyroid gland function in uremic patients.
• The stimulation test may aid in therapeutic planning, but optimal protocols require further definition.
• Scintigraphic uptake intensity correlates with parathyroid gland activity in uremic hyperparathyroidism.